AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14551476 — intervention group
Group type: COMPARATOR
Intervention: No vaccination (n = 101)
Number of subjects: 3771
Study 10971421 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (9 mmHg)
Number of subjects: 90
Study 10971421 — intervention group
Group type: COMPARATOR
Intervention: Normal-pressure pneumoperitoneum (13 mmHg)
Number of subjects: 90
Study 8792892 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 40
Study 8792892 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine with droperidol (10mg droperidol/60 mg morphine)
Number of subjects: 40
Study 1599353 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg of sustained-release pseudoephedrine taken twice daily
Number of subjects: 28
Study 1599353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6229262 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol (5 mg)
Number of subjects: 20
Study 6229262 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium (0.5 mg)
Number of subjects: 20
Study 6229262 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nebulised salbutamol and ipratropium
Number of subjects: 20
Study 6229262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29905663 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) for MST-related PTSD
Number of subjects: 32
Study 26952223 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium-codeine phosphate (Group NC)
Number of subjects: 61
Study 26952223 — intervention group
Group type: COMPARATOR
Intervention: naproxen sodium (Group N)
Number of subjects: 61
Study 24716522 — intervention group
Group type: EXPERIMENTAL
Intervention: PNF stretching training
Number of subjects: 49
Study 24716522 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 24096258 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (375 ml, 41 g of alcohol)
Number of subjects: 25
Study 24096258 — intervention group
Group type: COMPARATOR
Intervention: De-alcoholized red wine (equivalent volume)
Number of subjects: 25
Study 24096258 — intervention group
Group type: COMPARATOR
Intervention: Water (equivalent volume)
Number of subjects: 25
Study 21226862 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (1.5 mg/kg)
Number of subjects: 60
Study 21226862 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium (0.9 mg/kg)
Number of subjects: 60
Study 18654010 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients (DM group)
Number of subjects: 46
Study 18654010 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients (control group)
Number of subjects: 46
Study 18654010 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 16571909 — intervention group
Group type: EXPERIMENTAL
Intervention: Trace feedback
Number of subjects: 0
Study 16571909 — intervention group
Group type: COMPARATOR
Intervention: Cursor feedback
Number of subjects: 0
Study 12852989 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusional ambulatory chronotherapy with 5‐FU, folinic acid (FOL) and carboplatin
Number of subjects: 45
Study 10976785 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists
Number of subjects: 0
Study 9104623 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 26
Study 9104623 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride placebo
Number of subjects: 26
Study 9104623 — intervention group
Group type: EXPERIMENTAL
Intervention: Stridor score
Number of subjects: 26
Study 9104623 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone pre-treatment
Number of subjects: 26
Study 9104623 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic impairment
Number of subjects: 26
Study 7924782 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine infusion
Number of subjects: 10
Study 7924782 — intervention group
Group type: EXPERIMENTAL
Intervention: SRIH infusion
Number of subjects: 10
Study 7924782 — intervention group
Group type: COMPARATOR
Intervention: Hyperglucagonemia study
Number of subjects: 10
Study 7924782 — intervention group
Group type: COMPARATOR
Intervention: High GH study
Number of subjects: 10
Study 7924782 — intervention group
Group type: COMPARATOR
Intervention: Control study with insulin, glucagon, and GH at replacement doses
Number of subjects: 10
Study 3172783 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.56 g/kg ethanol
Number of subjects: 12
Study 29357516 — intervention group
Group type: EXPERIMENTAL
Intervention: -12° head-down tilt (HDT) in ambient air (0.04% CO2)
Number of subjects: 6
Study 29357516 — intervention group
Group type: EXPERIMENTAL
Intervention: -12° head-down tilt (HDT) with 0.5% CO2
Number of subjects: 6
Study 29357516 — intervention group
Group type: COMPARATOR
Intervention: Control (0.04% CO2)
Number of subjects: 6
Study 28060545 — intervention group
Group type: EXPERIMENTAL
Intervention: AERAS-402 vaccine
Number of subjects: 72
Study 28060545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 25800900 — intervention group
Group type: EXPERIMENTAL
Intervention: TOMUS trial
Number of subjects: 0
Study 25800900 — intervention group
Group type: EXPERIMENTAL
Intervention: SISTEr trial
Number of subjects: 0
Study 25800900 — intervention group
Group type: EXPERIMENTAL
Intervention: Both studies
Number of subjects: 0
Study 24889937 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination budesonide/formoterol inhaler as maintenance and reliever therapy ('SMART') regimen
Number of subjects: 303
Study 24889937 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (combination budesonide/formoterol inhaler for maintenance and salbutamol as reliever)
Number of subjects: 303
Study 23110481 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablative fractional carbon dioxide laser treatment at pulse durations of 500, 1,000, 1,500, and 1,800 μs.
Number of subjects: 10
Study 20488910 — intervention group
Group type: EXPERIMENTAL
Intervention: 850 mg metformin three times a day for 4.3 years
Number of subjects: 390
Study 20488910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 18980926 — intervention group
Group type: EXPERIMENTAL
Intervention: Care by a pivot nurse in oncology
Number of subjects: 170
Study 18980926 — intervention group
Group type: COMPARATOR
Intervention: Usual care by clinic nurses
Number of subjects: 170
Study 15812205 — intervention group
Group type: COMPARATOR
Intervention: No analgesia (group A)
Number of subjects: 60
Study 15812205 — intervention group
Group type: COMPARATOR
Intervention: Endorectal enema of 1% lidocaine gel (group B)
Number of subjects: 60
Study 15812205 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal periprostatic block (group C)
Number of subjects: 60
Study 11920457 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (GEM) alone (Arm A)
Number of subjects: 107
Study 11920457 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM) plus Cisplatin (CDDP) (Arm B)
Number of subjects: 107
Study 10341691 — intervention group
Group type: EXPERIMENTAL
Intervention: Planimetry measurements
Number of subjects: 11
Study 10341691 — intervention group
Group type: EXPERIMENTAL
Intervention: Point counting measurements
Number of subjects: 11
Study 10341691 — intervention group
Group type: COMPARATOR
Intervention: Comparison of planimetry and point counting
Number of subjects: 11
Study 10341691 — intervention group
Group type: EXPERIMENTAL
Intervention: Planimetry
Number of subjects: 11
Study 9280994 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen/nitrous oxide (group I)
Number of subjects: 132
Study 9280994 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane in O2 and air (group II)
Number of subjects: 132
Study 9280994 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol in continuous infusion with O2 and air (group III)
Number of subjects: 132
Study 9280994 — intervention group
Group type: COMPARATOR
Intervention: CO2 pneumoperitoneum (all groups)
Number of subjects: 132
Study 1587065 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg losartan
Number of subjects: 6
Study 1587065 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg losartan
Number of subjects: 6
Study 1587065 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg losartan
Number of subjects: 6
Study 1587065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3956521 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol (5 mg t.i.d.)
Number of subjects: 12
Study 3956521 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 31366664 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Energy Planning (PEP) programme, duration 7-9 weeks
Number of subjects: 0
Study 31366664 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0
Study 30342875 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation group training programme with financial incentives (vouchers for being abstinent: €50 at the end of training, €50 after 3 months, €50 after 6 months, €200 after 12 months)
Number of subjects: 604
Study 30342875 — intervention group
Group type: COMPARATOR
Intervention: Control group received weekly 90‐min session of smoking cessation group training for 7 weeks without financial incentives
Number of subjects: 604
Study 27328023 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d for 1 year (group A)
Number of subjects: 350
Study 27328023 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 150 mg/d for 30 days followed by 75 mg/d until 1 year (group B)
Number of subjects: 350
Study 27328023 — intervention group
Group type: COMPARATOR
Intervention: Policosanol 40 mg/d for 6 months and clopidogrel 75 mg/d for 1 year (group C)
Number of subjects: 350
Study 25537204 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy for RPE65-LCA
Number of subjects: 15
Study 22546535 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat exercises on a vibratory platform (platform group, n=11)
Number of subjects: 32
Study 22546535 — intervention group
Group type: EXPERIMENTAL
Intervention: Squat exercises without vibration (squat group, n=10)
Number of subjects: 32
Study 22546535 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=11)
Number of subjects: 32
Study 19566584 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics and prebiotics
Number of subjects: 237
Study 19566584 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 237
Study 18544723 — intervention group
Group type: EXPERIMENTAL
Intervention: H. perforatum (St John's wort) 300 mg standardized to 0.3% hypericin, taken 3 times daily for 8 weeks
Number of subjects: 54
Study 18544723 — intervention group
Group type: COMPARATOR
Intervention: Placebo, matched to H. perforatum, taken 3 times daily for 8 weeks
Number of subjects: 54
Study 18544723 — intervention group
Group type: EXPERIMENTAL
Intervention: H. perforatum (St John's wort)
Number of subjects: 54
Study 18544723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 15809508 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (750-3,000 mg/day)
Number of subjects: 800
Study 15809508 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (1,500-9,000 mg/day)
Number of subjects: 800
Study 11808976 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated CD patients
Number of subjects: 45
Study 11808976 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated CD patients
Number of subjects: 45
Study 11808976 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 45
Study 10781212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 800 mg three times a day
Number of subjects: 131
Study 10781212 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg three times a day
Number of subjects: 131
Study 10781212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 7723797 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES) exposure in utero
Number of subjects: 548
Study 7723797 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES) exposure before the 11th week of gestation
Number of subjects: 548
Study 7723797 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol (DES) exposure
Number of subjects: 548
Study 9114906 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhaled from a Turbuhaler (1 mg)
Number of subjects: 8
Study 3987794 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 12
Study 3987794 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 12
Study 3987794 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 12
Study 3987794 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 29994922 — intervention group
Group type: EXPERIMENTAL
Intervention: Xbox-Kinect games (Bowling and 20,000 leaks)
Number of subjects: 11
Study 27501616 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine 30 mL (Gr. B)
Number of subjects: 90
Study 27501616 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of 0.5% bupivacaine 20 mL and 2% lidocaine 10 mL (Gr. BL)
Number of subjects: 90
Study 24671522 — intervention group
Group type: EXPERIMENTAL
Intervention: EC aspirin 100 mg od
Number of subjects: 72
Study 24671522 — intervention group
Group type: COMPARATOR
Intervention: EC aspirin 100 mg bid
Number of subjects: 72
Study 24671522 — intervention group
Group type: COMPARATOR
Intervention: EC aspirin 200 mg od
Number of subjects: 72
Study 24671522 — intervention group
Group type: COMPARATOR
Intervention: Plain aspirin 100 mg od
Number of subjects: 72
Study 22571201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (10 mg per day, range 5 to 15)
Number of subjects: 460
Study 22571201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 22571201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 460
Study 20522357 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg intrathecal morphine with 8 mg hyperbaric bupivacaine and continuous epidural infusion of 0.2% ropivacaine at 6 mL/hr
Number of subjects: 76
Study 20522357 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg intrathecal morphine with 8 mg hyperbaric bupivacaine and continuous epidural infusion of 0.2% ropivacaine at 6 mL/hr
Number of subjects: 76
Study 20522357 — intervention group
Group type: COMPARATOR
Intervention: 0 microg intrathecal morphine with 8 mg hyperbaric bupivacaine and continuous epidural infusion of 0.2% ropivacaine at 6 mL/hr
Number of subjects: 76
Study 17931798 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Prognostic Assessment (GPA)
Number of subjects: 1960
Study 17931798 — intervention group
Group type: EXPERIMENTAL
Intervention: Recursive Partitioning Analysis (RPA)
Number of subjects: 1960
Study 17931798 — intervention group
Group type: COMPARATOR
Intervention: Other indices (not specified)
Number of subjects: 1960
Study 16382040 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenomethionine
Number of subjects: 0
Study 16382040 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 12480802 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated isoflavone group (n = 20)
Number of subjects: 40
Study 12480802 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 20)
Number of subjects: 40
Study 10360493 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave frequency of 1 per second (low frequency)
Number of subjects: 114
Study 10360493 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockwave frequency of 4 per second (high frequency)
Number of subjects: 114
Study 8770849 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg r‐ProUK over 60 minutes
Number of subjects: 131
Study 8770849 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg r‐ProUK over 90 minutes
Number of subjects: 131
Study 8770849 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg r‐ProUK over 60 minutes (primed with recombinant urokinase)
Number of subjects: 131
Study 8770849 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg r‐ProUK over 90 minutes (primed with recombinant urokinase)
Number of subjects: 131
Study 8770849 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐ProUK
Number of subjects: 131
Study 2202709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dehydroemetine and metronidazole
Number of subjects: 33
Study 2202709 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 33
Study 2202709 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg
Number of subjects: 33
Study 2202709 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole 800 mg
Number of subjects: 33
Study 6999618 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol (TAP) 1.5 g daily for 14 days
Number of subjects: 29
Study 6999618 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) 0.48 g TMP and 2.4 g SMZ daily for 14 days
Number of subjects: 29
Study 31200107 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation (cTBS) over SMA
Number of subjects: 20
Study 31200107 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation over SMA
Number of subjects: 20
Study 28698326 — intervention group
Group type: EXPERIMENTAL
Intervention: MiYoga intervention (mindfulness movement programme based on hatha yoga principles)
Number of subjects: 36
Study 28698326 — intervention group
Group type: EXPERIMENTAL
Intervention: MiYoga intervention
Number of subjects: 36
Study 28698326 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 36
Study 25769412 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrigenetic-guided diet (n=30)
Number of subjects: 51
Study 25769412 — intervention group
Group type: COMPARATOR
Intervention: Standard balanced diet (n=21)
Number of subjects: 51
Study 24041216 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 6
Study 24041216 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 6
Study 21394639 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC) 600 mg PO
Number of subjects: 38
Study 21394639 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) with orange juice
Number of subjects: 38
Study 20098804 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with myocardial infarction (MI)
Number of subjects: 49
Study 17210881 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase plus heparin sodium
Number of subjects: 0
Study 17210881 — intervention group
Group type: COMPARATOR
Intervention: Heparin alone
Number of subjects: 0
Study 15515199 — intervention group
Group type: EXPERIMENTAL
Intervention: New vaginal cone
Number of subjects: 120
Study 15515199 — intervention group
Group type: COMPARATOR
Intervention: FES-Biofeedback
Number of subjects: 120
Study 15515199 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 120
Study 11589932 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (perindopril 4 mg daily, with optional indapamide)
Number of subjects: 6105
Study 11589932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study 11589932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (perindopril plus indapamide)
Number of subjects: 6105
Study 11589932 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-drug therapy (perindopril alone)
Number of subjects: 6105
Study 9751239 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaspan 1.5 g at bedtime
Number of subjects: 223
Study 9751239 — intervention group
Group type: COMPARATOR
Intervention: Plain niacin 1.5 g/d after 8 weeks
Number of subjects: 223
Study 7942122 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA stimulation of human alveolar macrophages, blood monocytes, PMN and lymphocytes
Number of subjects: 0
Study 7942122 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific stimulus IgE/anti-IgE
Number of subjects: 0
Study 7942122 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemiluminescence assays
Number of subjects: 0
Study 7942122 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-imaging camera
Number of subjects: 0
Study 2896429 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone therapy (M)
Number of subjects: 30
Study 2896429 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal desensitization (ID)
Number of subjects: 30
Study 2896429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both imaginal desensitization and medroxyprogesterone (ID + M)
Number of subjects: 30
Study 2896429 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-responders)
Number of subjects: 30
Study 30069876 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapler hepatectomy
Number of subjects: 138
Study 30069876 — intervention group
Group type: COMPARATOR
Intervention: LigaSure™ transection
Number of subjects: 138
Study 28028836 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist-taught PE conducted by specialist PE teachers in 13 schools (two 45-minute sessions/week) from grade 2 to grade 6.
Number of subjects: 359
Study 28028836 — intervention group
Group type: COMPARATOR
Intervention: Common-practice PE taught by general classroom teachers in 16 schools (30-60 min/week).
Number of subjects: 359
Study 25669180 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airways Pressure (CPAP)
Number of subjects: 2717
Study 25669180 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2717
Study 23302902 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Number of subjects: 0
Study 23302902 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 20798428 — intervention group
Group type: EXPERIMENTAL
Intervention: myofeedback‐based teletreatment
Number of subjects: 139
Study 20798428 — intervention group
Group type: COMPARATOR
Intervention: usual treatment
Number of subjects: 139
Study 17534379 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (1.0 mg/h)
Number of subjects: 39
Study 17534379 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4 mc/kg)
Number of subjects: 39
Study 17534379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39